84 completed, 18 recruiting, 9 terminated, 7 active not recruiting. 47 Phase 1, 38 Phase 2, 18 Phase 3, 10 Not applicable, 3 Phase 4.
Follow Biomedical Advanced Research and Development Authority: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario Sample Collection - Infections, Bacterial | Phase 4 | Not yet recruiting | Emergent BioSolutions | 100 | 2027-01-01 | 2026-02-06 |
| A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects Fosmanogepix, Placebo, The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam) - Healthy Adult Participants | Phase 1 | Recruiting | Basilea Pharmaceutica | 42 | 2026-10-01 | 2026-10-19 |
| A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections Amicidin-β topical solution - 15 mL, Amicidin-β topical solution - 50 mL, Standard of Care (SOC) - Surgical Wound Infection, Traumatic Wound Infection | Phase 1 | Recruiting | Macro Biologics, Inc. | 44 | 2026-09-30 | 2026-08-17 |
| Observational, Non-interventional Biomarker and Endotyping Study ARDS (Acute Respiratory Distress Syndrome) | Recruiting | Prenosis, Inc. | 1200 | 2026-09-14 | 2026-09-28 | |
| Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults Placebo, Fostamatinib - Acute Respiratory Distress Syndrome, ARDS | Phase 2 | Not yet recruiting | Inova Health Care Services | 40 | 2026-08-30 | 2026-02-02 |
| A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women Gepotidacin - Urinary Tract Infections | Phase 1 | Recruiting | GlaxoSmithKline | 8 | 2026-07-23 | 2026-09-30 |
| A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health rVSVΔG-SUDV-GP, Placebo - Sudan Virus Disease | Phase 1 | Recruiting | International AIDS Vaccine Initiative | 112 | 2026-05-08 | 2026-09-21 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health rVSV∆G-MARV-GP, Placebo - Marburg Virus Disease | Phase 1 | Recruiting | International AIDS Vaccine Initiative | 112 | 2026-03-27 | 2026-09-23 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab Cohort C: bevacizumab, Cohort C: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-10-28 | 2026-07-31 |
| A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls S-892216-PO - Renal Impairment | Phase 1 | Completed | Shionogi | 24 | 2025-10-16 | 2026-10-22 |
| A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment Cefiderocol/Xeruborbactam - Bacterial Infections | Phase 1 | Completed | Qpex Biopharma, Inc. | 40 | 2025-09-16 | 2026-09-25 |
| A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) AZD4117, AZD5315, Placebo - Influenza A | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 405 | 2025-09-04 | 2026-10-09 |
| A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet - Invasive Mold Infections | Phase 3 | Recruiting | Basilea Pharmaceutica | 234 | 2025-08-26 | 2026-09-14 |
| A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults cAd3-Sudan Vaccine, Placebo - Ebola Sudan Virus Disease | Phase 2 | Active not recruiting | Albert B. Sabin Vaccine Institute | 200 | 2025-06-26 | 2026-02-10 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab Cohort A: vilobelimab, Cohort A: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-06-21 | 2026-07-31 |
| A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults Debio 1453P, Placebo - Healthy Participants | Phase 1 | Recruiting | Debiopharm International SA | 88 | 2025-06-18 | 2026-09-22 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) Cohort A: vilobelimab, Cohort A: placebo, Cohort B: paridiprubart - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 600 | 2025-06-10 | 2026-07-31 |
| JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart Cohort B: paridiprubart, Cohort B: placebo - Acute Respiratory Distress Syndrome (ARDS), ARDS | Phase 2 | Recruiting | PPD Development, LP | 200 | 2025-06-10 | 2026-07-31 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis Meropenem-Vaborbactam, Antibiotics - Acute Pyelonephritis, Complicated Urinary Tract Infection | Phase 2 | Active not recruiting | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 66 | 2025-06-03 | 2026-09-10 |
| Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP Cefepime-taniborbactam, Meropenem - Ventilator-associated Pneumonia, Hospital-acquired Pneumonia | Phase 3 | Withdrawn | Venatorx Pharmaceuticals, Inc. | 2025-06-01 | 2025-06-08 |
Showing 20 of 129. Sign in to see all of them.
COVID-19 (22) · Bacterial Infections (13) · Influenza, Human (12) · Anthrax (7) · Virus Diseases (7) · Respiratory Distress Syndrome (6) · Acute Lung Injury (5) · Sepsis (5) · Smallpox (5) · Burns (4) · Infections (4) · Marburg Virus Disease (4) · Respiratory Tract Infections (4) · Coronavirus Infections (3) · Influenza in Birds (3)
Sodium Chloride (8) · Ceftibuten (4) · MF59 oil emulsion (4) · QPX7728 (4) · Saline Solution (4) · tecovirimat (4) · Standard of Care (3) · gepotidacin (3) · 2019-nCoV Vaccine mRNA-1273 (2) · Amoxicillin-Potassium Clavulanate Combination (2) · Atropine (2) · BNT162 Vaccine (2) · Biothrax (2) · Cefiderocol (2) · GSK2798745 (2)
United States (110) · Bulgaria (8) · Australia (7) · Spain (7) · Belgium (5) · Germany (5) · Greece (5) · Italy (5) · Mexico (5) · Argentina (4) · Brazil (4) · France (4) · India (4) · Israel (4) · Netherlands (4)
Ernesto Ramirez, PhD (3) · Jeffery S Loutit, MBChB (3) · Carlos Fierro, MD (2) · Dennis Hruby, PhD (2) · Derek Eisnor, MD (2) · Jeff Loutit, MBChB (2) · Marc Engelhardt, MD (2) · Robert Shalwitz, MD (2) · Thomas Kaindl, MD (2) · Adam Wolfberg, MD (1) · Ajay Gupta, MD (1) · Alexandra Hill, MD (1)
PMID 34473343, PMID 36202997, PMID 36682364, PMID 29972742, PMID 30638863, PMID 31209461, PMID 31978354, PMID 32657946, PMID 32897367, PMID 33129609, PMID 33378609, PMID 33632249, PMID 33707061, PMID 33960817, PMID 34130619, PMID 34379915, PMID 34401888, PMID 34526698, PMID 34551225, PMID 35145311, PMID 35241844, PMID 35455245, PMID 35535503, PMID 35785530, PMID 36055877, PMID 36172138, PMID 36203544, PMID 36376733, PMID 36460535, PMID 36519984, PMID 36951890, PMID 37075127, PMID 37330602, PMID 37385888, PMID 37428480, PMID 37754204, PMID 38059635, PMID 38252170, PMID 38662372, PMID 39012102, PMID 39209823, PMID 39225478, PMID 39261482, PMID 39332418, PMID 39389071, PMID 39610848, PMID 39651882, PMID 39679349, PMID 39898869, PMID 40028879
2017 (3), 2019 (1), 2023 (1)